The current landscape of locally advanced rectal cancer

Abstract

Postoperative adjuvant chemoradiotherapy was recommended as the standard treatment for patients with rectal cancer because it reduces local recurrence. This paradigm shifted with the use of neoadjuvant chemoradiotherapy, which not only reduces local recurrence but also improves sphincter preservation and surgical outcomes. However, the treatment of rectal carcinoma remains complicated. The accuracy of tumor staging can be compromised depending on the imaging modality used. The addition of modern chemotherapeutics and biologics to 5-fluorouracil as radiation sensitizers is questionable. Oxaliplatin as a radiation sensitizer has minimal effects on the pathologic complete response, but improves the radiographical response at the expense of an increased risk of toxicities. The role of biologics in addition to radiation therapy continues to be explored. Attention has focused on improving diagnostic imaging, radiation oncology, and surgical techniques, treatment regimens, and on exploring a role of molecular markers for patients with rectal cancers. We review the pivotal trials that have led to the current treatment paradigm for locally advanced rectal cancer and discuss novel methodologies that are being developed for the treatment of this prevalent malignancy.

Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: Opportunities for signaling-adapted therapies

“…Currently, no consensus exists to whether systemic therapy may reduce the risk of metastatic development in rectal cancer [5,8]. The use of postoperative adjuvant chemotherapy, as being given in colon cancer, has been adopted at a number of centers internationally despite the lack of evidence-based data [9]. In most Nordic countries, postoperative treatment is offered only on specific, individual-based indications.…”

Potential suppressive effects of theophylline on human rectal cancer SW480 cells in�vitro by inhibiting YKL-40 expression

“…To the best of our knowledge, the cause of the disease remains unknown, and surgical resection is the main treatment modality for the therapy of rectal cancer; however, 30% of these patients develop disease recurrence and metastasis (2). Therefore, studies investigating novel therapeutic strategies, particularly molecular targeted agents, have become a topic of substantial interest.…”

Personalized radiotherapy: concepts, biomarkers and trial design

“…88 Yet, there is compelling evidence that longterm survival benefit is contingent on considerable or factual complete tumour response, 89 supporting the notion that elimination of tumour clonogens is essential for favourable therapeutic results. Specifically, a substantial number of patients with LARC, reported to be 30-40% of cases in recent studies, 90,91 will experience metastatic progression.…”